311 – 320 of 459
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2003
-
Mark
Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable
(
- Contribution to journal › Article
-
Mark
Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies
(
- Contribution to journal › Article
-
Mark
Expression and immunolocalisation of neutral endopeptidase in prostate cancer
(
- Contribution to journal › Article
-
Mark
Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3)
(
- Contribution to journal › Article
-
Mark
Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
(
- Contribution to journal › Article
-
Mark
Expression of protein C inhibitor (PCI) in benign and malignant prostatic tissues
(
- Contribution to journal › Article
- 2002
-
Mark
Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
(
- Contribution to journal › Article
-
Mark
Sensitive and specific enzymatic assay for the determination of precursor forms of prostate-specific antigen after an activation step
(
- Contribution to journal › Article
-
Mark
Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer
(
- Contribution to journal › Article
-
Mark
Measurement of the noncomplexed free fraction of tissue inhibitor of metalloproteinases I in plasma by immunoassay
(
- Contribution to journal › Article